This leads to improved cell viability in HD mice and patients, suggesting that laduviglusib may enhance mitochondrial function in HD neurons by targeting the CAST/calpain/Drp1 pathway, rather than GSK3, thus providing protection against HD. Here, DNM1L is linked to Huntington disease.